[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth",
    "summary": "Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=71cf21e21234cf3bda986be1e260de11d1d45175fd328d278b414e699475b587",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753711217,
      "headline": "Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth",
      "id": 136108381,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=71cf21e21234cf3bda986be1e260de11d1d45175fd328d278b414e699475b587"
    }
  },
  {
    "ts": null,
    "headline": "GSK: I Foresee Only Very Modest Upside Here Even If Blenrep Gets FDA Approval",
    "summary": "GSK's stable dividend and strong portfolio face modest growth amid competition and legal risks.",
    "url": "https://finnhub.io/api/news?id=f2c1ff55466555a16146f2862081ba3107b08e25c2042e9d05eca444184afeb2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753706498,
      "headline": "GSK: I Foresee Only Very Modest Upside Here Even If Blenrep Gets FDA Approval",
      "id": 136107253,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2177313278/image_2177313278.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "GSK's stable dividend and strong portfolio face modest growth amid competition and legal risks.",
      "url": "https://finnhub.io/api/news?id=f2c1ff55466555a16146f2862081ba3107b08e25c2042e9d05eca444184afeb2"
    }
  },
  {
    "ts": null,
    "headline": "Canaccord Reiterates a Buy Rating on Regeneron Pharmaceuticals (REGN)",
    "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the most profitable biotech stocks to invest in now. Canaccord updated estimates on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on July 24, reiterating a Buy rating on the stock with an $850 price target. The firm stated that it anticipates weakness to continue in EYLEA sales for Q2 2025, primarily […]",
    "url": "https://finnhub.io/api/news?id=58fc4fbc31e81ccb85b4431e3448ecdbcb79cb848d7d885de1ceca4bdaa60729",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753682854,
      "headline": "Canaccord Reiterates a Buy Rating on Regeneron Pharmaceuticals (REGN)",
      "id": 136108646,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the most profitable biotech stocks to invest in now. Canaccord updated estimates on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on July 24, reiterating a Buy rating on the stock with an $850 price target. The firm stated that it anticipates weakness to continue in EYLEA sales for Q2 2025, primarily […]",
      "url": "https://finnhub.io/api/news?id=58fc4fbc31e81ccb85b4431e3448ecdbcb79cb848d7d885de1ceca4bdaa60729"
    }
  }
]